FLT3‐ITD + NPM1 mutation
|
AML
|
FLT3‐ITD + NPM1 mutation
|
AML
|
gilteritinib Sensitive: B - Late Trials
|
gilteritinib Sensitive: B - Late Trials
|
FLT3‐ITD + NPM1 mutation
|
AML
|
FLT3‐ITD + NPM1 mutation
|
AML
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|